- Home
- EHAB vs ADCT Comparison
EHAB vs ADCT Comparison
Compare EHAB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHAB
- ADCT
- Stock Information
- Founded
- EHAB 2014
- ADCT 2011
- Country
- EHAB United States
- ADCT Switzerland
- Employees
- EHAB N/A
- ADCT N/A
- Industry
- EHAB Hospital/Nursing Management
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- EHAB Health Care
- ADCT Health Care
- Exchange
- EHAB Nasdaq
- ADCT Nasdaq
- Market Cap
- EHAB 409.1M
- ADCT 398.2M
- IPO Year
- EHAB N/A
- ADCT 2020
- Fundamental
- Price
- EHAB $7.60
- ADCT $3.30
- Analyst Decision
- EHAB Buy
- ADCT Strong Buy
- Analyst Count
- EHAB 3
- ADCT 6
- Target Price
- EHAB $8.67
- ADCT $7.80
- AVG Volume (30 Days)
- EHAB 385.0K
- ADCT 583.2K
- Earning Date
- EHAB 11-05-2025
- ADCT 11-06-2025
- Dividend Yield
- EHAB N/A
- ADCT N/A
- EPS Growth
- EHAB N/A
- ADCT N/A
- EPS
- EHAB N/A
- ADCT N/A
- Revenue
- EHAB $1,037,800,000.00
- ADCT $77,246,000.00
- Revenue This Year
- EHAB $4.95
- ADCT $13.10
- Revenue Next Year
- EHAB $4.33
- ADCT $6.23
- P/E Ratio
- EHAB N/A
- ADCT N/A
- Revenue Growth
- EHAB N/A
- ADCT 15.73
- 52 Week Low
- EHAB $6.47
- ADCT $1.05
- 52 Week High
- EHAB $10.91
- ADCT $3.97
- Technical
- Relative Strength Index (RSI)
- EHAB 44.79
- ADCT 52.25
- Support Level
- EHAB $7.57
- ADCT N/A
- Resistance Level
- EHAB $8.16
- ADCT $3.38
- Average True Range (ATR)
- EHAB 0.23
- ADCT 0.16
- MACD
- EHAB -0.04
- ADCT -0.13
- Stochastic Oscillator
- EHAB 11.11
- ADCT 92.05
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).